Antiplatelet medications are drugs that prevent blood cells called platelets from clumping together to form clots. They’re one of the most widely prescribed drug classes in cardiovascular medicine, used primarily to lower the risk of heart attacks and strokes. Aspirin, the oldest and most familiar antiplatelet, remains a cornerstone of treatment, but several newer and more potent options now exist.
How Platelets Form Clots
Platelets are tiny cell fragments circulating in your blood. When you cut your finger, they rush to the site, stick together, and form a plug that stops the bleeding. This is normal and essential. The problem starts when platelets form clots inside blood vessels, particularly in arteries already narrowed by fatty plaque buildup.
When plaque inside an artery ruptures, it triggers a chain reaction. Your body releases chemical signals, including a molecule called ADP and a compound called thromboxane A2, that activate nearby platelets. Those activated platelets change shape, expose sticky binding sites on their surface, and link together through bridges made of a protein called fibrinogen. More chemical signals recruit even more platelets, and the clot grows rapidly. If it blocks blood flow to your heart, you have a heart attack. If it blocks flow to your brain, you have a stroke. Antiplatelet drugs interrupt this chain reaction at different points, making it harder for platelets to activate and stick together.
The Three Main Classes
Antiplatelet medications fall into three broad categories based on where they interrupt the clotting process.
Aspirin (COX-1 Inhibitors)
Aspirin blocks an enzyme that platelets need to produce thromboxane A2, one of the key chemical signals that drives clot formation. Low doses, typically 75 to 150 mg daily, are enough to nearly completely shut down this pathway. Higher doses don’t improve the antiplatelet effect much but do increase the risk of stomach bleeding, which is why most people on long-term aspirin therapy take a low dose.
P2Y12 Inhibitors
These drugs block the receptor that responds to ADP, another major activation signal. The most commonly prescribed are clopidogrel, prasugrel, and ticagrelor. All three are taken orally, but they differ in important ways. Clopidogrel has been used the longest but works more slowly and has more variability between patients: some people’s livers don’t convert it into its active form efficiently. Prasugrel and ticagrelor are more potent, kick in faster, and produce more consistent effects. Ticagrelor has the added distinction of being reversible, meaning its effects wear off more predictably when you stop taking it. An intravenous option called cangrelor also exists for hospital use when rapid, short-acting platelet inhibition is needed.
Glycoprotein IIb/IIIa Inhibitors
These are the most powerful antiplatelets. They block the final common step in clot formation: the receptor on the platelet surface that fibrinogen bridges latch onto. Because they’re only available as intravenous drugs, they’re reserved for acute situations like heart attacks being treated in the hospital, not for daily home use.
Why They’re Prescribed
The primary reason people take antiplatelet medications is to prevent a second heart attack or stroke after they’ve already had one. This is called secondary prevention, and the evidence for benefit here is strong. Aspirin alone reduces the incidence of further heart attacks, strokes, and death from vascular causes in people who’ve already had a cardiovascular event.
After a heart attack or a stent procedure, most patients are placed on dual antiplatelet therapy: aspirin plus a P2Y12 inhibitor. This combination significantly reduces the chance of another major cardiac event compared to aspirin alone. The standard duration is 6 to 12 months, though the exact length depends on the type of stent, the patient’s bleeding risk, and whether the original problem was a heart attack or a stable blockage. European guidelines tend to allow shorter courses (as few as 6 months), while American guidelines generally default to at least 12 months.
For people who have never had a heart attack or stroke, the picture is more nuanced. The U.S. Preventive Services Task Force recommends against starting aspirin for primary prevention in adults 60 or older, because the bleeding risks outweigh the benefits. For adults 40 to 59 with a 10-year cardiovascular risk of 10% or higher, it’s an individual decision. The net benefit in this group is small, and it mainly applies to people who aren’t already at elevated risk for bleeding.
Bleeding Risk: The Main Tradeoff
Because these drugs reduce your blood’s ability to clot, bleeding is the most significant side effect. In a large real-world study, about 36 out of every 10,000 patients on antiplatelet therapy experienced a major bleeding event. The most common site was the gastrointestinal tract, particularly the upper GI tract (stomach and upper intestines). Bleeding inside the skull was less common but more dangerous.
The risk roughly doubles when you’re on two antiplatelet drugs instead of one. Combinations of aspirin with prasugrel or ticagrelor carry higher bleeding rates than aspirin with clopidogrel, which is the flip side of their greater potency. Higher doses of aspirin also increase risk: patients on high-dose aspirin had about 1.8 times the rate of bleeding inside the skull compared to those on low-dose aspirin. This is a core reason why the lowest effective dose is preferred for long-term use.
How They Differ From Blood Thinners
People often confuse antiplatelets with anticoagulants (commonly called blood thinners), like warfarin or the newer direct oral anticoagulants. They both prevent clots, but they work on completely different parts of the clotting system. Antiplatelets block platelet activation. Anticoagulants inhibit clotting factors, the proteins in your blood plasma that form the mesh-like structure of a clot. In simple terms, antiplatelets target the cellular component of a clot, while anticoagulants target the protein component.
This distinction matters clinically. Antiplatelets are the go-to treatment for arterial clots, the kind that cause heart attacks and most strokes. Anticoagulants are preferred for clots that form in veins (like deep vein thrombosis) or in the heart’s chambers due to irregular rhythms like atrial fibrillation. Some patients need both, but that combination significantly raises bleeding risk and requires careful management.
Stopping Before Surgery
If you’re on antiplatelet therapy and need surgery, your care team will likely ask you to stop certain medications beforehand to reduce the risk of excessive bleeding during the procedure. The general timeline is 5 days before surgery for clopidogrel and ticagrelor, and 7 days for prasugrel. Aspirin is often continued through surgery because its bleeding risk during most procedures is manageable.
There are exceptions. For surgeries where even minor bleeding could be catastrophic, such as brain surgery, spinal surgery near the spinal cord, or surgery on the back of the eye, both the P2Y12 inhibitor and aspirin may need to stop 7 days in advance. The timing matters because these drugs affect platelets for their entire lifespan, and your body needs days to produce enough fresh, unaffected platelets to clot normally. Never stop antiplatelet medications on your own before a procedure, because stopping too early after a stent placement can trigger the very clot the medication was preventing.